- Aktuelle Seite:
-
Home
-
Substitutionsmittel
- Buprenorphin
Evaluation of the effects of a monthly buprenorphine depot subcutaneous injection on qt interval during treatment for opioid use disorder.
Schmith VD, Curd L, Lohmer LRL, Laffont CM, Andorn A, Young MA.
Clin Pharmacol Ther. 2019 Feb 22. doi: 10.1002/cpt.1406.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30801681
Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study.
Lugoboni F, Zamboni L, Cibin M, Tamburin S; Gruppo InterSERT di Collaborazione Scientifica (GICS).
Eur Addict Res. 2019;25(1):10-19. doi: 10.1159/000496112.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30625491
Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Haight, Barbara RAndersen, James L. et al.
Lancet. 2019 Feb 18. pii: S0140-6736(18)32259-1. doi: 10.1016/S0140-6736(18)32259-1.
Abstract
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32259-1/fulltext
Monthly buprenorphine injections effective for opioid use disorders
Study results on long-acting injection formulation now published. (NIH – National Institutes of Health, USA, 19.02.2019)
Lund/Mannheim, 12. Februar 2019 – Wie Camurus (NASDAQ STO: CAMX) heute bekannt gab, ist das wöchentlich oder monatlich anzuwendende Buvidal® (Buprenorphin-Depotlösung zur subkutanen Injektion) ab sofort in Deutschland verfügbar. Buvidal® ist das erste in Europa zugelassene Depotpräparat zur Behandlung der Opioidabhängigkeit bei Erwachsenen und Jugendlichen ab 16 Jahren. (Camurus, Pressemitteilung vom 12.02.2019)
PM_Camurus_Launch_Buvidal_12022019.pdf
No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study.
Latif ZE, Solli KK, Opheim A, Kunoe N, Benth JŠ, Krajci P, Sharma-Haase K, Tanum L.
Am J Addict. 2019 Jan 31. doi: 10.1111/ajad.12859.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30701613
Buprenorphine for the treatment of posttraumatic stress disorder.
Lake EP, Mitchell BG, Shorter DI, Kosten T, Domingo CB, Walder AM.
Am J Addict. 2019 Jan 21. doi: 10.1111/ajad.12860.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30664299
Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression.
Lin C, Karim HT, Pecina M, Aizenstein HJ, Lenze EJ, Blumberger DM, Mulsant BH, Kharasch ED, Reynolds Iii CF, Karp JF.
Neuroimage Clin. 2019 Jan 22;21:101679. doi: 10.1016/j.nicl.2019.101679. https://www.sciencedirect.com/science/article/pii/S2213158219300294
Use of Generally Recognized as Safe or Dietary Compounds to Inhibit Buprenorphine Metabolism: Potential to Improve Buprenorphine Oral Bioavailability.
Maharao N, Venitz J, Gerk PM.
Biopharm Drug Dispos. 2018 Dec 5. doi: 10.1002/bdd.2166.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30520057
Care-by-parent model as a tool for reduction in neonatal opioid withdrawal syndrome in neonates exposed to buprenorphine maintenance therapy in-utero.
Lawlor ML, Shook L, McQuerry K, Srinivasan A, Johnson QB, Chavan NR, Critchfield AS.
J Matern Fetal Neonatal Med. 2018 Dec 18:1-111. doi: 10.1080/14767058.2018.1558201.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30563376
Impact of Fentanyl Use on Buprenorphine Treatment Retention and Opioid Abstinence.
Wakeman SE, Chang Y, Regan S, Yu L, Flood J, Metlay J, Rigotti N.
J Addict Med. 2018 Dec 13. doi: 10.1097/ADM.0000000000000486.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30550392
Single high-dose buprenorphine for opioid craving during withdrawal.
Ahmadi J, Jahromi MS, Ghahremani D, London ED.
Trials. 2018 Dec 10;19(1):675. doi: 10.1186/s13063-018-3055-z.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288888/
Intravenous buprenorphine/naloxone and concomitant oral pregabalin misuse: a case report.
Kulaksızoğlu B, Kara H, Bodur B, Kuloğlu M.
Neuropsychiatr Dis Treat. 2018 Nov 9;14:3033-3035. doi: 10.2147/NDT.S179688. eCollection 2018.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233699/
Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.
Fava M, Memisoglu A, Thase ME, Bodkin JA, Trivedi MH, de Somer M, Du Y, Leigh-Pemberton R, DiPetrillo L, Silverman B, Ehrich E.
Am J Psychiatry. 2016 May 1;173(5):499-508. doi: 10.1176/appi.ajp.2015.15070921.
https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.2015.15070921
EU-Zulassung für Buprenorphin-Depotlösung
Berlin- Methadon, Levomethadon, Buprenorphin und Diamorphin können zur Substitutionstherapie opioidabhängiger Patienten eingesetzt werden. In Europa wurde nun die erste Buprenorphin-haltige Depotinjektion zugelassen, die Markteinführung in den einzelnen Ländern ist für das erste Quartal 2019 geplant. (APOTHEKE ADHOC, 04.12.2018)
A clinical trial on the acute effects of methadone and buprenorphine on actual driving and cognitive function of healthy volunteers.
Strand, M. C., Vindenes, V., Gjerde, H., Mørland, J. G., and Ramaekers, J. G. (2018)
Br J Clin Pharmacol, doi.org/10.1111/bcp.13818
https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/bcp.13818
Utilizing Buprenorphine in the Emergency Department after Overdose
Johns, Sade E. et al.
Trends in Pharmacological Sciences , Volume 39 , Issue 12 , 998 - 1000
https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(18)30180-9
Efficacy of buprenorphine and clonidine in opioid detoxification: A hospital- based study.
Jain N, Chavan BS, Sidana A, Das S.
Indian J Psychiatry. 2018 Jul-Sep;60(3):292-299. doi: 10.4103/psychiatry.IndianJPsychiatry_381_17.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201659/
Camurus: Die Europäische Kommission erteilt die Marktzulassung für wöchentliche und monatliche Buvidal®-Depotinjektionen zur Behandlung von Opioidabhängigkeit
Lund, Schweden - Buvidal® ist die erste in der EU zugelassene Depotinjektion mit Langzeitwirkung zur Behandlung von Opioidabhängigkeit bei Erwachsenen und Jugendlichen. ((ots/PRNewswire, 22.11.2018)
https://www.presseportal.de/pm/110796/4123405
Camurus: Transforming treatments by long-acting medications
Fredrik Tiberg, President & CEO
Pdf-Präsentation zu CAM 2038, Weekly and monthly buprenorphine depots - Changing the treatment paradigm in opioid dependence (ohne Datum)
Treatment of Kratom Withdrawal and Addiction With Buprenorphine.
Khazaeli A, Jerry JM, Vazirian M.
J Addict Med. 2018 Nov/Dec;12(6):493-495. doi: 10.1097/ADM.0000000000000435.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30383616
Methadone to buprenorphine/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting-Azar method.
Azar P, Nikoo M, Miles I.
Am J Addict. 2018 Nov 2. doi: 10.1111/ajad.12809.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30387894
CHMP recommends approval of Buvidal® (CAM2038) for the treatment of opioid dependence
On approval, Buvidal® would be the first long-acting medicine for treatment of opioid dependence in the EU
A final decision by the European Commission is expected November 2018. (Camurus, 21.09.2018)
Understanding the use of diverted buprenorphine.
Cicero TJ, Ellis MS, Chilcoat HD.
Drug Alcohol Depend. 2018 Oct 12;193:117-123. doi: 10.1016/j.drugalcdep.2018.09.007.
https://www.ncbi.nlm.nih.gov/pubmed/30359928
Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine.
Gilman M, Li L, Hudson K, Lumley T, Myers G, Corte C, Littlewood R.
Patient Prefer Adherence. 2018 Oct 11;12:2123-2129. doi: 10.2147/PPA.S180641.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188959/
Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder.
Ronquest NA, Willson TM, Montejano LB, Nadipelli VR, Wollschlaeger BA.
Subst Abuse Rehabil. 2018 Sep 21;9:59-78. doi: 10.2147/SAR.S150253.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165853/
High buprenorphine-related mortality is persistent in Finland.
Kriikku P, Häkkinen M, Ojanperä I.
Forensic Sci Int. 2018 Aug 17;291:76-82. doi: 10.1016/j.forsciint.2018.08.010.
Abstract
https://www.sciencedirect.com/science/article/pii/S0379073818305073?via%3Dihub
Buprenorphine Formulations for the Treatment of Opioid Use Disorders: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness and Guidelines [Internet].
Harricharan S, Farah K.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jul 31.
https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0099978/
MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study.
Schuman-Olivier Z, Borodovsky JT, Steinkamp J, Munir Q, Butler K, Greene MA, Goldblatt J, Xie HY, Marsch LA.
Addict Sci Clin Pract. 2018 Sep 24;13(1):21. doi: 10.1186/s13722-018-0122-4.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154900/
USA. OxyContin maker gets patent for drug to treat opioid addiction
Purdue Pharma, the maker of OxyContin, has received a patent designed to treat opioid addiction.
The patent, first reported by The Financial Times, is for a new and faster-acting form of buprenorphine. (CBS-News, Money Watch, USA, 07.08.2018)
https://www.cbsnews.com/news/oxycontin-maker-receives-patent-for-drug-to-treat-opioid-addiction/
Seite 1 von 7